HRMY / Harmony Biosciences to buy Zynerba Pharmaceuticals for up to $200 million

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Rege more_horizontal

Harmony Biosciences' only product, WAKIX - pitolisant - has generated over $1 billion in net revenue since its launch. The company's Q2 2023 earnings more_horizontal

Harmony has already gotten approval for the drug to treat adults with excessive daytime sleepiness who have narcolepsy. Harmony's second-quarter reven more_horizontal

Harmony Biosciences Holdings Inc shares sank 38% to $18.66 in late-morning trading on Friday after the pharmaceutical company reported topline results more_horizontal

Harmony Biosciences has experienced strong and profitable growth following the approval and commercialization of WAKIX. The company's success has allo more_horizontal

PLYMOUTH MEETING, Pa. , Sept. 13, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutica more_horizontal

Shares of Zynerba Pharmaceuticals Inc. ZYNE, +0.89% jumped 300% premarket on Monday after Harmony Biosciences Holdings Inc. HRMY, -0.47% said it would more_horizontal

Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.56 per share, missing the Zacks Consensus Estimate of $0.62 per share more_horizontal